Implementation of a Peer Leader-facilitated Dyadic Intervention
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Oct 15, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new program aimed at reducing the risk of heart disease and diabetes among first-generation Asian Indian immigrants. The program, called the CHAI Dyad study, involves couples (marital dyads) working together under the guidance of peer leaders for 12 weeks. Participants will join weekly classes that mix in-person and online learning, where they will learn about healthier lifestyles, including diet and exercise. The goal is to help couples address various challenges that can increase their risk of cardiovascular disease, such as stress from adjusting to a new culture and unhealthy eating habits.
To be eligible for this trial, you need to be a community-dwelling first-generation Asian Indian immigrant, between the ages of 18 and 70, and able to read and write in English. You must also be comfortable using technology. If selected, you will either participate in the intervention program or receive standard lifestyle advice for heart health. This study is not yet recruiting participants, but it aims to find out how effective and acceptable this program is for those involved.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • community-dwelling first generation Asian Indian (AI) immigrants (in marital dyads) between the ages of 18-70 years of age who can read and write English and are technology literate.
- Exclusion Criteria:
- • AIs not in a marital dyad, those below the age of 20 or above 70 years or those born in the US or visiting the US from India.
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Karen T D'Alonzo, PhD
Principal Investigator
Rutgers, The State University of New Jersey
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported